To join a class action against a pharmaceutical company, you need to first confirm that a lawsuit exists for the drug or device that harmed you, then consult an attorney who handles drug injury cases, and finally establish your eligibility by documenting the connection between your medication use and your health problems. In many cases, you may already be part of the class without knowing it — some plaintiffs receive mail notification that they have been included based on prescription records, and the only action required is deciding whether to stay in or opt out. Attorneys in these cases typically work on contingency, meaning you pay nothing upfront.
This process matters now more than ever. Class action settlements hit a record high in 2025, with corporations paying out $79 billion total, including $17.9 billion in product liability cases covering defective drugs, devices, and consumer products. Major pharmaceutical actions currently working through the courts include the Zantac litigation covering approximately 80,000 lawsuits, the Depo-Provera brain tumor cases centralized in federal court in Florida, and ongoing opioid settlements that have surpassed $54 billion in total restitution. This article walks through the specific steps for joining one of these cases, the legal requirements you should understand, the deadlines that could affect your rights, and what to realistically expect from the process.
Table of Contents
- What Are the Steps to Join a Class Action Lawsuit Against a Pharmaceutical Company?
- Legal Requirements and Federal Rules Governing Pharmaceutical Class Actions
- Statutes of Limitations and Why Timing Matters in Drug Injury Cases
- How to Evaluate Whether Joining a Class Action or Filing Individually Is the Right Choice
- Common Obstacles and Limitations When Joining Pharmaceutical Class Actions
- What Happens After You Join a Pharmaceutical Class Action
- The Outlook for Pharmaceutical Class Actions in 2026 and Beyond
- Frequently Asked Questions
What Are the Steps to Join a Class Action Lawsuit Against a Pharmaceutical Company?
The process begins with determining whether a class action or mass tort already exists for the drug that caused your injury. Cases are generally referred to by the drug’s name — the “Ozempic lawsuit,” the “Depo-Provera lawsuit,” and so on. A quick search or a call to a drug injury attorney can confirm whether litigation is active. If no class action exists yet, an attorney can evaluate whether your situation warrants filing a new claim or joining an emerging action. The distinction matters because pharmaceutical litigation sometimes takes the form of multidistrict litigation (MDL) rather than a traditional class action, and the two have different procedural mechanics for joining. Once you have confirmed that a case exists, the next step is consulting with a qualified attorney. Drug injury lawyers typically advance all costs and collect fees only if the case results in a settlement or verdict.
This contingency arrangement means there is no financial barrier to getting legal advice. The attorney will then help you establish eligibility, which requires demonstrating that you suffered the same type of harm alleged by other plaintiffs. Medical records, pharmacy records, and documentation showing a link between your medication use and your health problems form the backbone of this proof. The final step depends on the status of the case. If a class action has been certified by the court, you may be automatically included as a class member and would need to actively opt out if you wanted to pursue your own individual lawsuit instead. In other situations — particularly in MDLs or cases that have not yet been certified — you must submit a claim form or have your attorney file paperwork to formally include you. Failing to act before deadlines expire can permanently forfeit your right to compensation.
Legal Requirements and Federal Rules Governing Pharmaceutical Class Actions
class actions in federal court are governed by Federal Rule of Civil Procedure 23, which sets out the requirements a case must meet before a judge will certify it as a class action. Among the key requirements is that the claims of the representative plaintiffs must be “typical of the claims or defenses of the class.” In pharmaceutical cases, this means the named plaintiffs must have experienced injuries representative of what the broader group suffered — a requirement that can be difficult to meet when a drug causes a wide range of side effects at different severity levels. This is one reason many pharmaceutical cases proceed as MDLs rather than certified class actions. In an MDL, individual cases are consolidated before a single federal judge for pretrial proceedings, but each plaintiff retains their own claim.
The Depo-Provera meningioma litigation, for example, is centralized as an MDL in the Middle District of Florida against Pfizer, alleging failure to warn about brain tumor risks from long-term use. Plaintiffs in that case each have individual claims, but they benefit from shared discovery and coordinated pretrial work. However, if your situation does not closely match the injuries alleged by the majority of plaintiffs, you may find that a class action or MDL is not the best vehicle for your claim. Individuals with unusually severe injuries sometimes recover more through individual lawsuits, though this comes with greater financial risk and longer timelines. An attorney can help you weigh whether staying in the class or opting out serves your interests better.
Statutes of Limitations and Why Timing Matters in Drug Injury Cases
One of the most critical factors in pharmaceutical litigation is the statute of limitations — the legal deadline for filing a claim. For pharmaceutical product liability, this window generally ranges from one to six years depending on the state, with two to three years being the most common timeframe. The discovery rule applies in most jurisdictions, meaning the clock may start when you discovered (or reasonably should have discovered) that the drug caused your injury, not when you first took the medication. Filing a class action has an important protective effect on timing. When a class action is filed, it suspends the statute of limitations for all class members while the court determines whether to certify the case.
This means class members cannot be accused of “sleeping on their rights” while the litigation is pending. For example, if a class action was filed in 2023 and certification is still being decided in 2026, class members generally will not have their claims time-barred during that period — even if their individual statute of limitations would have otherwise expired. That said, this tolling protection is not absolute. If a court denies class certification, the clock starts running again, and plaintiffs who waited may find themselves scrambling to file individual claims before time runs out. The Ultragenyx Pharmaceutical securities fraud class action illustrates the importance of deadlines — stockholders who purchased shares between August 3, 2023 and December 26, 2025 face a lead plaintiff deadline of April 6, 2026. Missing that date means losing the opportunity to serve as a lead plaintiff, though it does not necessarily bar participation in the class itself.
How to Evaluate Whether Joining a Class Action or Filing Individually Is the Right Choice
The decision between joining a class action and filing an individual lawsuit involves real tradeoffs. Class actions offer lower risk and lower cost — you share attorneys, share litigation expenses, and do not need to personally manage the case. But the compensation in a class action is typically divided among all members, which can result in modest individual payouts even when the total settlement is large. In the generic drug price-fixing litigation, a $275 million settlement was approved in February 2025 against Sandoz for conspiring to fix prices, but that amount is spread across a large class of affected purchasers. Individual lawsuits, by contrast, allow plaintiffs to present the full scope of their personal damages. Someone who suffered a serious brain tumor from Depo-Provera use, for instance, may have medical bills, lost income, and pain and suffering that far exceed what a per-plaintiff class action payout would cover.
Filing individually preserves the right to seek full compensation. The downside is significant: individual cases are expensive to litigate, may take years to resolve, and carry the risk of losing entirely. A middle ground exists in some pharmaceutical litigation. In bellwether trials within an MDL, a handful of representative cases go to trial first, and the outcomes influence settlement negotiations for the remaining cases. The Zantac litigation followed a version of this approach — GlaxoSmithKline reached private settlement agreements covering approximately 80,000 lawsuits in Delaware Superior Court, estimated at up to $2.2 billion, negotiated with 10 major plaintiffs’ firms and expected to be fully implemented by mid-2025. Individual claim values within such settlements often vary based on the severity of each plaintiff’s injuries.
Common Obstacles and Limitations When Joining Pharmaceutical Class Actions
Not every drug injury qualifies for inclusion in a class action. Courts require that class members share common questions of law or fact, and pharmaceutical cases can fracture along lines of different injuries, different drug formulations, or different prescribing circumstances. If a drug caused liver damage in some patients and kidney damage in others, those groups may not qualify as a single class. Plaintiffs whose injuries fall outside the scope of the certified class may need to pursue separate litigation. Documentation is another frequent barrier. To establish eligibility, you need medical records showing both that you took the drug and that you suffered the alleged harm.
Patients who received medication samples, purchased drugs from unregulated sources, or lack continuous medical records may struggle to prove their connection to the class. Pharmacy records, insurance claims, and physician notes all serve as supporting evidence, and gathering these documents should be an early priority. There is also no guarantee of recovery. Class actions can be dismissed, decertified, or result in settlements that provide less compensation than plaintiffs expected. The opioid litigation offers a cautionary perspective — while over $54 billion in total restitution has been committed from manufacturers and distributors, the money flows primarily to state and local governments rather than individual users. As of late 2024, more than $4.3 billion had reached government coffers, and on January 23, 2025, 15 states announced a $7.4 billion agreement with Purdue Pharma and the Sackler family. Individual claimants in the Purdue bankruptcy received far less than government entities.
What Happens After You Join a Pharmaceutical Class Action
Once you are part of a class action or MDL, the waiting begins. Pharmaceutical litigation routinely takes years from filing to resolution. During this time, you may be asked to provide additional medical records, answer written questions (interrogatories), or sit for a deposition. Your attorney handles the bulk of the legal work, but your cooperation with document requests and medical authorizations is essential to keeping your claim viable.
Settlement offers can arrive at various stages. Some defendants settle early to limit exposure; others fight through trial. When a settlement is reached, class members typically receive notice and have the opportunity to submit a claim form detailing their injuries. Payouts are then distributed based on a formula that accounts for injury severity, duration of drug use, and other factors. In the Zantac settlements, for instance, individual compensation amounts will likely vary significantly depending on whether a plaintiff developed cancer and the type of cancer involved.
The Outlook for Pharmaceutical Class Actions in 2026 and Beyond
The record $79 billion in class action settlements paid by corporations in 2025 signals that pharmaceutical companies face growing legal and financial exposure. Antitrust cases led the way at nearly $46 billion, but product liability — the category covering defective drugs and devices — accounted for $17.9 billion. With ongoing litigation around Depo-Provera, continuing opioid settlements, and emerging cases involving newer drugs, the pipeline of pharmaceutical class actions shows no signs of slowing.
For consumers, this trend means both greater opportunity and greater complexity. More lawsuits create more avenues for compensation, but they also require more careful evaluation of which legal vehicle — class action, MDL, or individual suit — best fits a particular situation. Staying informed about active litigation, preserving medical records, and consulting with an attorney sooner rather than later remain the most effective steps anyone can take to protect their rights.
Frequently Asked Questions
Do I need to pay an attorney to join a pharmaceutical class action?
No. Drug injury attorneys work on contingency, meaning they advance all costs and only collect fees if the case results in a settlement or verdict. You pay nothing out of pocket.
How do I know if a class action exists for my drug?
Search for the drug name followed by “lawsuit” or “class action,” or contact a drug injury attorney directly. Cases are typically referred to by the drug’s brand name. Reliable legal news sources and court docket databases can confirm whether litigation is active.
Can I be part of a class action without knowing it?
Yes. If a class action is certified and you fall within the defined class — for example, anyone who purchased a specific drug during a certain time period — you may be automatically included. You would typically receive a notice by mail explaining your options, including the right to opt out.
What is the difference between a class action and an MDL?
In a class action, one or more plaintiffs represent the entire group, and the outcome binds all class members. In a multidistrict litigation (MDL), individual cases are consolidated for pretrial proceedings but each plaintiff retains a separate claim. Many pharmaceutical cases, such as the Depo-Provera litigation, proceed as MDLs rather than traditional class actions.
How long does a pharmaceutical class action take?
Most take several years from filing to resolution. The Zantac litigation, for example, involved approximately 80,000 lawsuits before reaching settlement agreements expected to be fully implemented by mid-2025. Timelines vary depending on the complexity of the case and whether it goes to trial.
What if the statute of limitations has passed for my claim?
The discovery rule may extend your deadline if you only recently learned that a drug caused your injury. Additionally, a pending class action suspends the statute of limitations for all class members while class certification is being determined. Consult an attorney to evaluate whether your claim is still timely.
You Might Also Like
- How to File a Class Action Lawsuit Against a Hospital for Malpractice
- How to File a Class Action Claim If the Company No Longer Exists
- What Tax Form Do You Receive for a Class Action Settlement Payment